Amycretin (Zenagamtide)
Also known as: Zenagamtide, Amycretin
Amycretin — now assigned the international nonproprietary name zenagamtide — is a single peptide that agonizes both the GLP-1 and amylin receptors, combining two distinct appetite pathways in one molecule.
Last updated
Mechanism of Action
Amycretin is a unimolecular peptide agonist of both the GLP-1 receptor and the amylin receptor. Rather than co-formulating two drugs, a single molecule engages both pathways: GLP-1 receptor agonism drives incretin signaling, slowed gastric emptying and central appetite suppression, while amylin receptor agonism promotes satiation and suppresses post-prandial glucagon. Engaging both in one molecule is intended to produce additive metabolic effects with a simpler pharmacokinetic profile than a two-drug combination.
- Half-life
- Formulated for once-weekly subcutaneous administration; exact half-life not publicly characterized
- Administration Routes
- subcutaneous
- Research Status
- Clinical
Reported Benefits
- A1c reduction of 1.71 points at 40 mg in phase 2 type 2 diabetes (1.56-point treatment difference vs placebo, p<0.0001)
- 89.1% of participants reached A1c below 7% at the top dose
- Weight loss up to 14.6% vs 2.1% placebo in a type 2 diabetes population
- Dose-dependent response observed across all six doses studied
- Single molecule rather than a co-formulated combination
- Once-weekly subcutaneous dosing
Potential Side Effects
- Gastrointestinal effects consistent with GLP-1 receptor agonism (nausea, vomiting, diarrhea)
- Full tolerability profile at phase 3 scale not yet established
- Long-term safety unknown
- No human safety data outside monitored trial settings
Common Dosing
No established human dosing outside clinical trials. The phase 2 type 2 diabetes trial evaluated six once-weekly subcutaneous doses from 0.4 mg to 40 mg over 36 weeks. Amycretin is investigational and not approved for human use. Not medical or dosing advice.
The dosing information above is aggregated from research literature and anecdotal community reports for educational purposes only. It is not a recommendation, prescription, or medical advice. Peptides are sold as research chemicals only and are not intended for human use.
Contraindications
- Not approved for human use in any jurisdiction
- Pregnancy and breastfeeding
- Personal or family history of medullary thyroid carcinoma or MEN2 (class-wide precaution for GLP-1 receptor agonists)
No documented stacking partners for Amycretin (Zenagamtide) yet.
- View
Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial
2025
- View
Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study
2025
- View
Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial
2026
- View
The effect of amycretin, a unimolecular glucagon-like peptide-1 and amylin receptor agonist, on body weight and metabolic dysfunction in mice and rats
2025